DK3655401T3 - Tlr7/8-antagonister og anvendelser deraf - Google Patents
Tlr7/8-antagonister og anvendelser deraf Download PDFInfo
- Publication number
- DK3655401T3 DK3655401T3 DK18749977.7T DK18749977T DK3655401T3 DK 3655401 T3 DK3655401 T3 DK 3655401T3 DK 18749977 T DK18749977 T DK 18749977T DK 3655401 T3 DK3655401 T3 DK 3655401T3
- Authority
- DK
- Denmark
- Prior art keywords
- tlr7
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533820P | 2017-07-18 | 2017-07-18 | |
| PCT/US2018/042417 WO2019018354A1 (en) | 2017-07-18 | 2018-07-17 | ANTAGONISTS OF TLR7 / 8 AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3655401T3 true DK3655401T3 (da) | 2023-10-30 |
Family
ID=63104070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18749977.7T DK3655401T3 (da) | 2017-07-18 | 2018-07-17 | Tlr7/8-antagonister og anvendelser deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10793553B2 (da) |
| EP (2) | EP3655401B1 (da) |
| JP (2) | JP7239554B2 (da) |
| CN (1) | CN110944990B (da) |
| AU (1) | AU2018302026B2 (da) |
| CA (1) | CA3070171A1 (da) |
| DK (1) | DK3655401T3 (da) |
| ES (1) | ES2965044T3 (da) |
| IL (1) | IL272016B2 (da) |
| WO (1) | WO2019018354A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3889145T1 (sl) | 2015-12-17 | 2024-05-31 | Merck Patent Gmbh | 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj |
| DK3497094T3 (da) | 2016-08-08 | 2023-05-15 | Merck Patent Gmbh | Tlr7/8-antagonister og anvendelser deraf |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| TW202016105A (zh) | 2018-06-12 | 2020-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於治療自體免疫疾病的新穎雜芳基雜環基化合物 |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| MX2021000093A (es) * | 2018-07-31 | 2021-03-25 | Merck Patent Gmbh | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. |
| JP7233809B2 (ja) | 2018-09-04 | 2023-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのベンゾチアゾール化合物 |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| US11504425B2 (en) | 2019-02-26 | 2022-11-22 | Wayne State University | Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers |
| EP4164646A1 (en) * | 2020-06-15 | 2023-04-19 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| TWI803246B (zh) * | 2021-03-18 | 2023-05-21 | 大陸商成都百裕製藥股份有限公司 | 喹啉衍生物及其在醫藥上的應用 |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| JP2024513945A (ja) | 2021-04-16 | 2024-03-27 | ギリアード サイエンシーズ， インコーポレイテッド | チオノピロール化合物 |
| US12070455B2 (en) | 2021-09-10 | 2024-08-27 | Gilead Sciences, Inc. | Thienopyrrole compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358949A (en) * | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
| JPH01156960A (ja) * | 1987-09-24 | 1989-06-20 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| IL155089A0 (en) * | 2000-10-12 | 2003-10-31 | Merck & Co Inc | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| BR0313405A (pt) * | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US7268232B2 (en) * | 2004-05-17 | 2007-09-11 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| US20090042857A1 (en) * | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20090170898A1 (en) * | 2006-03-31 | 2009-07-02 | Malena Bengtsson | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor |
| EP1920654A1 (en) * | 2006-09-13 | 2008-05-14 | Syngeta Participations AG | Novel pyridopyrazine N-oxides |
| CL2008001002A1 (es) * | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| CA2728559A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| JP2011529932A (ja) * | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| AU2010357625B2 (en) * | 2010-07-16 | 2015-04-23 | Mallinckrodt Llc | (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof |
| WO2012167046A1 (en) * | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| WO2013060881A1 (en) * | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| KR102365952B1 (ko) * | 2013-10-14 | 2022-02-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| KR102103256B1 (ko) | 2013-10-14 | 2020-04-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| CA2933767C (en) * | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| SI3889145T1 (sl) * | 2015-12-17 | 2024-05-31 | Merck Patent Gmbh | 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj |
-
2018
- 2018-07-17 DK DK18749977.7T patent/DK3655401T3/da active
- 2018-07-17 CA CA3070171A patent/CA3070171A1/en active Pending
- 2018-07-17 EP EP18749977.7A patent/EP3655401B1/en active Active
- 2018-07-17 JP JP2020502368A patent/JP7239554B2/ja active Active
- 2018-07-17 ES ES18749977T patent/ES2965044T3/es active Active
- 2018-07-17 WO PCT/US2018/042417 patent/WO2019018354A1/en unknown
- 2018-07-17 US US16/037,368 patent/US10793553B2/en active Active
- 2018-07-17 CN CN201880047783.5A patent/CN110944990B/zh active Active
- 2018-07-17 EP EP23189231.6A patent/EP4248968A3/en active Pending
- 2018-07-17 AU AU2018302026A patent/AU2018302026B2/en active Active
-
2020
- 2020-01-13 IL IL272016A patent/IL272016B2/en unknown
- 2020-08-13 US US16/947,691 patent/US10836750B1/en active Active
-
2023
- 2023-03-02 JP JP2023031649A patent/JP2023065588A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018302026A1 (en) | 2020-03-05 |
| US10793553B2 (en) | 2020-10-06 |
| IL272016A (en) | 2020-02-27 |
| JP7239554B2 (ja) | 2023-03-14 |
| US20190023687A1 (en) | 2019-01-24 |
| CN110944990B (zh) | 2024-06-18 |
| US20200369648A1 (en) | 2020-11-26 |
| US10836750B1 (en) | 2020-11-17 |
| WO2019018354A1 (en) | 2019-01-24 |
| AU2018302026B2 (en) | 2022-04-07 |
| EP3655401B1 (en) | 2023-09-06 |
| JP2020527577A (ja) | 2020-09-10 |
| JP2023065588A (ja) | 2023-05-12 |
| IL272016B2 (en) | 2023-02-01 |
| IL272016B (en) | 2022-10-01 |
| EP4248968A3 (en) | 2023-12-06 |
| EP3655401A1 (en) | 2020-05-27 |
| ES2965044T3 (es) | 2024-04-10 |
| CN110944990A (zh) | 2020-03-31 |
| CA3070171A1 (en) | 2019-01-24 |
| EP4248968A2 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3497094T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| DK3655401T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
| IL275463A (en) | TLR7/8 antagonists and their use | |
| IL272910A (en) | Ectonucleotide pyrophosphate-phosphodiesterase 1 (ENPP-1) inhibitors and their uses | |
| DK3478811T3 (da) | Rengøringssammensætninger og anvendelser deraf | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3607069T3 (da) | Produkter og sammensætninger | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| DK3411398T3 (da) | Målrettede terapeutiske midler og anvendelse heraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3268470T3 (da) | Transposasepolypeptider og anvendelser deraf | |
| SG11202100818RA (en) | Tlr7/8 antagonists and uses thereof | |
| DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3692015T3 (da) | Hidtil ukendte glutaminantagonister og anvendelser deraf | |
| DK3621694T5 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3423076T3 (da) | Topisk cyclosporinholdige formuleringer og anvendelser deraf | |
| DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf |